Related Experiment Video
Updated: Apr 4, 2026
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled
Jessica Lefebvre1, Roland Antaki1, Isaac-Jacques Kadoch1
1OVO Clinic, Department of Obstetrics and Gynecology, University of Montreal, Montreal, Quebec, Canada; Clinique de Procréation Assistée du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Objective:
To compare the outcomes of controlled ovarian stimulation/in vitro fertilization cycles using 450 IU and 600 IU gonadotropin per day in women at risk of poor ovarian response.
Design:
Prospective randomized controlled nonblinded study.
Setting:
University-affiliated private IVF center.
Patient(S):
Women considered to be at risk of poor ovarian response: aged <41 years with basal FSH >10 IU/L, antimüllerian hormone <1 ng/mL, antral follicle count ≤ 8, or a previous IVF cycle with ≥ 300 IU/d gonadotropin that resulted in a cancellation, <8 follicles, or <5 oocytes.
Intervention(S):
A total of 356 patients underwent a microdose GnRH agonist flare-up IVF/intracytoplasmic sperm injection protocol with a fixed daily dose of either 450 IU FSH (n = 176) or 600 IU FSH (n = 180) equally divided between Menopur and Bravelle.
Main Outcome Measure(S):
Number of mature oocytes retrieved.
Result(S):
The two groups were similar in terms of age, ovarian reserve, cause of infertility, duration of stimulation, and cycle cancellation rate. There were no significant differences in the number of metaphase II oocytes retrieved (4 [range 0-6] vs. 4 [range 2-7]), fertilization rate (62.4% vs. 57.0%), biochemical pregnancy rate (20.5% vs. 22.9%), clinical pregnancy rate (16.4% vs. 18.3%), and implantation rate (29.8% vs. 30.4%) between the 450 IU and 600 IU groups, respectively.
Conclusion(S):
Gonadotropin of 600 IU/d does not improve outcome of IVF cycles compared with 450 IU/d in women at risk of poor ovarian response.
Clinical Trial Registration Number:
NCT00971152.
